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Background: The prognosis of patients bearing high grade glioma remains dismal. Epidermal Growth Factor
Receptor (EGFR) is well validated as a primary contributor of glioma initiation and progression. Nimotuzumab is a
humanized monoclonal antibody that recognizes the EGFR extracellular domain and reaches Central Nervous
System tumors, in nonclinical and clinical setting. While it has similar activity when compared to other anti-EGFR
antibodies, it does not induce skin toxicity or hypomagnesemia.
Methods: A randomized, double blind, multicentric clinical trial was conducted in high grade glioma patients
(41 anaplastic astrocytoma and 29 glioblastoma multiforme) that received radiotherapy plus nimotuzumab or placebo.
Treatment and placebo groups were well-balanced for the most important prognostic variables. Patients received 6
weekly doses of 200 mg nimotuzumab or placebo together with irradiation as induction therapy. Maintenance
treatment was given for 1 year with subsequent doses administered every 3 weeks. The objectives of this study were
to assess the comparative overall survival, progression free survival, response rate, immunogenicity and safety.
Results: The median cumulative dose was 3200 mg of nimotuzumab given over a median number of 16 doses. The
combination of nimotuzumab and RT was well-tolerated. The most prevalent related adverse reactions included
nausea, fever, tremors, anorexia and hepatic test alteration. No anti-idiotypic response was detected, confirming the
antibody low immunogenicity. The mean and median survival time for subjects treated with nimotuzumab was 31.06
and 17.76 vs. 21.07 and 12.63 months for the control group.
Conclusions: In this randomized trial, nimotuzumab showed an excellent safety profile and significant survival benefit
in combination with irradiation.
Trial registration: Cuban National Register for clinical trials (No. 1745) (http://registroclinico.sld.cu/ensayos).
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High-grade gliomas (HGG) are the most common primary
tumors in the central nervous system (CNS) in adults [1].
Despite remarkable advances in cancer research and in
neurosurgery, radiotherapy and chemotherapy, these
patients still face a poor prognosis, pointing towards an
urgent need for new therapeutic approaches [2]. Standard
treatment for HGG usually entails surgery followed by
radiotherapy plus chemotherapy. Temozolomide is the
drug of choice since 2005 for glioblastoma multiforme
(GBM) patients [3], but unfortunately, it is not available in
Cuba, due to the commercial restrictions imposed by the
US embargo. However, since the survival benefit of
radio-chemotherapy is so limited [4], patients with
brain tumors are considered candidates for clinical
trials that evaluate new drugs, radiosensitizers or new
accelerated/hyperfractionated radiation schemes. Therefore,
we decided to evaluate the efficacy of radiation plus
an anti-EGFR antibody vs. radiation plus placebo in a
controlled double blind trial, in newly diagnosed patients
with grade III/IV astrocytomas.
The Epidermal Growth Factor Receptor (EGFR) is a
membrane-bound receptor that has been shown to have
a major role in the pathogenesis and progression of
different cancers [5]. EGFR is greatly expressed in
HGG patients and gene amplification represents one
of the most frequent alterations in this tumor type
[6]. Moreover, EGFR plays a fundamental role in
gliomagenesis. According Mazzoleni and co-workers,
cancer stem cells (CSC) isolated from glioma patients,
need to express EGFR to promote experimental
tumorigenesis and EGFR-expressing initiating cells
display the most malignant phenotype [7]. In summary,
EGFR is well validated as a primary contributor of HGG
initiation and progression [8].
Nimotuzumab is a humanized monoclonal antibody
that recognizes the EGFR extracellular domain. The
antibody was obtained by humanization of the murine
antibody ior egf/r3 [9]. Because nimotuzumab has a 10
fold lower affinity to the EGFR, as compared to
cetuximab, its capacity to bind EGFR is heavily dictated
by cell receptor density [10]. Nimotuzumab preclinical
and clinical characterizations have been summarized
before [11-13].
A distinguishing feature of nimotuzumab compared to
other mAbs of the EGFR class, is the lack of severe
skin toxicity as well as severe hypomagnesemia [14].
Two hypotheses have been posed to explain this lack
of skin toxicity of nimotuzumab: according Garrido
[10], nimotuzumab requires bivalent binding for stable
attachment to the cellular surface, leading to selectively
binding to cells that express moderate to high EGFR
levels. Accordingly, nimotuzumab will selectively target
tumors, and not normal tissues. Instead, Talavera built acomputer model of the nimotuzumab-EGFR complex
[15], where nimotuzumab blocks ligand binding, but
allows the receptor to adopt its active conformation,
warranting the basal level of signaling needed for the
survival of non-tumor cells [15].
This type of binding is analogous to the binding of
trastuzumab to the HER-2 receptor [16]. Nimotuzumab
safety profile permits up to 800 mg doses in adults [17] or
150–250 mg/m2 in children, without safety concerns [13].
In the nonclinical setting, nimotuzumab has been evalu-
ated in the glioma cell line U87MG. Co-administration of
the antibody with radiation increased the radiosensitivity,
resulting in a delay of tumor growth. The antibody reduced
angiogenesis and the total number of radioresistant cancer
stem cells [18].
In a separate study, nude mice that had an intra-cerebral
implant of the U87MG cell line were treated with
nimotuzumab labelled with 111Indium. Radioactivity was
measured after organ explantation. Results showed a clear
time-dependant increase in 111indium nimotuzumab uptake
in the tumour in contrast to all other organs [19].
The capacity of the antibody of crossing the blood–brain
barrier (BBB) was studied also by radioimmunscitigraphy
using nimotuzumab labelled with Technetium 99 (Tc99).
In a phase I/II trial, immunscitigraphy done after radiation
plus nimotuzumab, showed a positive MAb uptake by
patients with tumors, while subjects with complete
responses showed no antibody accumulation at the known
site of tumors [20]. In addition, it has been proposed that
in the fast-growing gliomas, the newly formed blood
vessels lack BBB function. As a consequence, MAbs such
as nimotuzumab may primarily enter a brain tumor
through tumor vessels that lack BBB [21,22].
To conclude, the nonclinical and clinical radiolabelled
study does support penetration of the brain. MRI scan
results in children with refractory brain tumors treated
with nimotuzumab alone also provided evidence of
nimotuzumab activity at the tumor site [13].
An open labeled study of the combination nimotuzumab
plus radiotherapy (RT)/temozolomide (TMZ) study was
conducted in Germany in 149 adult patients with newly
diagnosed GBM [23]. In this paper, we report the results of
a randomized, double blind clinical trial where 70 HGG
patients were treated with irradiation plus nimotuzumab
or placebo.
Methods
A randomized, double-blind, multicentric, Phase II clinical
trial was conducted in 70 HGG patients that received
irradiation plus either nimotuzumab or a placebo.
Sample size was calculated by anticipating a 6-month
improvement in median survival time with respect to
the baseline survival in the control group. The sample
size was calculated using a “sample size calculation”
Solomón et al. BMC Cancer 2013, 13:299 Page 3 of 8
http://www.biomedcentral.com/1471-2407/13/299software, Version 1.1, option 4: comparison of two means,
from the Institute of Medical Research in Barcelona.
Patients were recruited at 8 clinical sites. They were
subjected to maximal excision (total, partial resection or
biopsy) at least 4 weeks before the inclusion and were
candidates of radiotherapy. Other important inclusion
criteria included: age older than 18, Karnofsky performance
status (KPS) ≥ 60 and adequate bone marrow, liver and
renal function; subjects in fertile age were required to
possess a negative pregnancy test and to use an effective
contraceptive method. The primary objective of this study
was to assess the overall survival (OS) of nimotuzumab in
HGG patients when compared to the control group
receiving irradiation and placebo. The secondary objectives
were to assess progression-free survival (PFS), response rate
and the safety and immunogenicity of nimotuzumab in this
patient population. Eligible patients were randomized to
either group in a 1:1 ratio.
Random assignment was performed centrally through a
validated simple randomization system version 1.2. Patients
were previously stratified by histology (GBM vs. AA)
to ensure equal distribution in both groups. The
study was designed to include up to 30 GBM patients
while the rest were AA patients. Treatment dose was
200 mg of nimotuzumab, intravenously infused over
30 to 60 minutes. The control group received 4 vials
of a placebo composed by a saline buffer. Each subject
received a weekly infusion, for 6 weeks, concurrently with
the radiotherapy. After finishing induction therapy,
patients received, in double blind fashion, a maintenance
dose of 200 mg of nimotuzumab or 4 vials of placebo
every 21 days until completing 1 year of treatment.
Irradiation was delivered in doses of 180–200 cGy
given once daily, 5 days per week, to a total dose of 5000
cGy to 6000 cGy. Radiotherapy planning and simulation
was performed on the basis of recent CT scans. The
irradiation field encompassed the initial tumor volume
plus a security margin of 2 cm.
Before each dose, a physical examination of the major
body systems was conducted. Vital signs were measured
before and after each infusion. Hematology and bio-
chemistry tests were carried out previous to the first
dose and every 14 days for 6 weeks. Later on, sampling
was carried out every 21 days, until 1 year of study.
Adverse events were assigned severity/intensity categories
according the Common Terminology Criteria for Adverse
Events (CTCAE) version 3. The anti-idiotypic response
against nimotuzumab, was measured in 12 patients through
an indirect ELISA system validated at the Center of
Molecular Immunology, that has been previously described
[20]. For response evaluation, nuclear magnetic resonance
(MRI) or CT-scans were done before inclusion and then,
every 3 months. Response was classified according to
WHO modified criteria. Overall survival and progressionfree survival were analyzed using the Kaplan-Meier method
and the parametric Weibull regression survival model [24].
The Weibull Shape Parameter (WSP) test is very powerful
at detecting signals that occur shortly after starting
treatment [24].
The trial was performed in compliance with the Helsinki
Declaration. The protocol was approved by the Institutional
Review Boards of the 8 research sites: Calixto García
Hospital, Lucía Iñiguez Hospital, Center for Medical and
Surgical Research, Arnaldo Milián Hospital, Maria Curie
Hospital, Luis Díaz Soto Hospital, Hermanos Ameijeiras
Hospital and Saturnino Lora Hospital, as well as by the
National Regulatory Authority: the State Centre for Drug
Quality Control. All patients signed the informed consent
form. The protocol information was included on the
National Register for clinical trials (No. 1745) which is a pri-
mary register approved by the World Health Organization
(WHO) (http://registroclinico.sld.cu/ensayos).
Results
A total of 73 patients were included in the study: 43
patients with Anaplastic Astrocytoma (AA) and 30
patients with Glioblastoma Multiforme (GBM). Three
patients from the nimotuzumab arm (10, 54 and 61)
abandoned the study from inclusion and did not
receive any therapy. Information was available from
70 subjects: 41 AA and 29 GBM patients. In the AA
group, 41 patients were analyzed per intention to treat: 23
received placebo and 18 received nimotuzumab. In the
GBM group, 29 patients were analyzed, 15 of these received
placebo and 14 received nimotuzumab.
The trial started on June 2005 and was completed on
June 2010. Baseline characteristics are described in Table 1.
The groups were balanced for the most important
prognostic features: histology, age, surgical intervention
and KPS. In total, 32 patients received nimotuzumab
and RT while 38 patients were treated with irradiation
and a placebo. Nimotuzumab group received an average
dose of 2631 mg, although the median cumulative dose
was 3300 mg. The maximal administered dose was 3600
mg. The median number of doses was 16. Concerning
radiotherapy, the mean cumulative dose was 5556 cGy.
The combination of nimotuzumab and RT was
well-tolerated. More than 85% of the adverse events
in either group were categorized as grade 1 or 2 (mild
or moderate), according the CTCAE scale. Of these, only
15% were adverse reactions, which are, causally linked to
nimotuzumab. No dose reduction was required as a
consequence of an adverse event. In the placebo arm, the
most frequent adverse events consisted on headache,
seizures, dry radiodermitis, fever, asthenia, alopecia and
alteration of the liver function tests.
In the nimotuzumab arm, the most common adverse
reactions included nausea, tremors, anorexia, increase
Table 1 Patient demographic and tumor characteristics
Variables Number of patients Number of patients
(%) (%)
Control group Nimotuzumab patients
Sex
Male 19 (50%) 21 (65.6%)
Female 19 (50%) 11 (34.4%)
Race
White 31 (81.5%) 27 (84.3%)
Black 1 (2.6%) 2 (6.3%)





Younger than 50 21 (55.3%) 19 (59.4%)
Older than 50 17 (44.7%) 13 (40.6%)
Body weight
Mean 68.1 kg 69 kg
Median 65 kg 70 kg
Histology
AA 23 (60.5%) 18 (56.2%)
GBM 15 (39.5%) 14 (43.7%)
KPS
100 8 (21%) 9 (28.1%)
90 9 (23.6%) 10 (31.2%)
80 6 (15.8%) 8 (25%)
70 11 (28.9%) 2 (6.2%)
60 4 (10.5%) 3 (9.3%)
Previous surgery
Total 2 (5.4%) 5 (17.2%)
Partial 27 (72.9%) 14 (48.2%)
Biopsy 8 (21.6%) 10 (34.5%)
Table 2 Most frequent unrelated and related adverse
events after treatment with irradiation plus
nimotuzumab or placebo




Unrelated (Not related and unlikely)
Headache 42 17
Seizures 16 6
Dry radiodermitis 6 5
Fever 6
Asthenia 5 4
Liver function tests alterations 7 5
Alopecia 4 7
Possibly, probably or definitively related with nimotuzumab
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frequent adverse events unrelated to treatment were
headache, alopecia, seizures and radiodermitis. Overall,
serious adverse events included headache, vomiting,
seizures, brain edema, pneumonia, hemiparesis,
motor defects, disorientation, respiratory depression
and intracranial hypertension. All serious adverse
events were attributed to the natural course of the
disease and the neurological worsening associated
with HGG. None of the serious adverse events were
attributed to nimotuzumab. Table 2 summarizes the
most frequent unrelated and related toxicities for
both treatment groups.None of these patients developed anti-idiotypic re-
sponse against the murine residues of the humanized
molecule.
Antitumor response was confirmed for 33 patients in
the AA stratum (17 controls and 16 nimotuzumab treated
subjects) and 20 patients in the GBM arm (9 controls and
11 antibody treated subjects). No significant differences
were detected between the 2 groups in relation to overall
response or disease control rate. Objective response was
59.25% for nimotuzumab and 53.84%, for the placebo
arm. Disease control rate was 85.18% for the active drug
group vs. 84.61%, in the placebo cohort.
The mean and median survival time for the intent to
treat (ITT) population in the nimotuzumab cohort was
31.06 and 17.76 months, and 21.07 and 12.63 months for
those patients treated with placebo and irradiation
(HR=0,64). This difference was statistically significant
according the Weibull parametric model (Weibull statistics,
p = 0.032).
For AA patients, the mean and median survival time was
41.29 and 44.56 months, if they received nimotuzumab vs.
29.67 and 17.56 months for the control patients (Weibull
statistics, p = 0.311). For the GBM patients, mean and
median overall survival corresponded to 17.24 and 8.40
(nimotuzumab arm) vs. 9.84 and 8.36 months (placebo
arm), respectively (Weibull statistics, p = 0.026).
PFS was evaluated as a secondary endpoint. In the
ITT analysis, the mPFS was 15.73 months for
nimotuzumab + RT and 6.5 months for the control arm.
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for the whole population are illustrated at Figure 1.
Figure 2 presents the survival curves according
histology.
Discussion
Eventhough, chemo-radiotherapy is the standard of care
for anaplastic astrocytomas and glioblastoma multiforme,
patients’ prognosis remains very poor and the disease is
still incurable. Thus, enrolling this patient population in
clinical trials that evaluate new drug candidates is a very
appealing strategy. Novel biologic therapies under clinical
evaluation for patients with high grade glioma include
dendritic cell vaccination, tyrosine kinase receptor
inhibitors, farnesyl transferase inhibitors, viral-based
gene therapy, oncolytic viruses, vascular endothelial
growth factor inhibitors and Epidermal growth factor-
receptor inhibitors [25,26]. This manuscript illustrates
the results of combining irradiation and an anti-EGFR
antibody in a double blind trial that complements the
nimotuzumab add-on to temozolomide/irradiation study
in GBM, which is underway under a German sponsorship
in Europe [23].
Nimotuzumab was very well tolerated and the most
frequent adverse reactions consisted of grade 1/2 infusion
reactions. Remarkably, patients received a cumulative
dose of 3300 mg, which is much higher than the dose
administered in the previous Phase I trial (1200 mg)
and is probably the highest cumulative antibody dose
ever administered to glioma patients. After 16 doses
of nimotuzumab, there was no increasing toxicity
with repeated treatment. Radiation associated toxicity
was not exacerbated by the antibody. As reported in all
previous studies, nimotuzumab did not induce skin rashPatients at risk 0    10  20 30 40
nimotuzumab          32 23 14 12 11











Figure 1 Overall survival and progression free survival of patients tre[11-13,20,27 and 28]. No anti-idiotypic response was
detected, confirming nimotuzumab low immunogenicity.
Several EGFR inhibitors have been used to treat
HGG patients [29-42]. Cetuximab was administered
as monotherapy to recurrent glioma patients with an
acceptable safety profile [30]. The most frequent adverse
events have been acne-like rash (folliculitis/dermatitis)
together with xerodermia, paronichia, fissures at the
hands and/or feet, dermatitis of the eyelids, and increased
facial hair growth [30]. Alternatively, small tyrosine kinase
inhibitors have been used to treat recurrent or newly
diagnosed glioma patients. More than 10 clinical trials
using erlotinib or gefitinib, have been reported [31-42].
Globally, both drugs were well tolerated, being diarrhea
and rash the most common toxicity. The majority of these
events were mild or moderate, while grade 3 or higher
events were reported in one-third of the patients receiving
erlotinib in the recurrent scenario [31-36]. Strikingly,
one trial evaluating the combination of temozolomide,
radiotherapy and erlotinib was discontinued due to
unacceptable toxicity [39].
Regarding clinical outcome, patients achieved a signifi-
cant improvement in overall survival, if they received
nimotuzumab and irradiation. However, this result
should be interpreted with caution since even though no
significant differences were detected between the 2
groups regarding the most important prognostic factors,
more patients with poorer KPS and no debulking surgery
were included to the control group.
Nimotuzumab has been evaluated before in combination
with irradiation and temozolimide for the treatment of
newly diagnosed GBM patients. In a trial conducted at 11
hospitals in Germany, patients were randomized to arm A























Patients at risk 0 10 20 30 40
nimotuzumab         32 21 12 11 10
control 38 17 8 6 5
Progression Free Survival
ated with radiotherapy and nimotuzumab or placebo.
Patients at risk 0 10  20 30 40 50 Patients at risk 0 10 20 30 40 50 
nimotuzumab          14 7 3 3 nimotuzumab         18 14 10 8 7 4
control                     15 6 1 control 23 15 9 6 5
Overal survivall (GBM) Overall survival (AA)
Figure 2 Overall survival of GBM and AA patients treated with radiotherapy and nimotuzumab or placebo.
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19.6 months for groups A and B that were comparable with
the results of Hegi of 21.7 (RT/TMZ) vs. 15.3 months (RT)
for patients with methylated MGMT [24], and better
than Stupp’s of 14.6 (RT/TMZ) and 12.1 months (RT)
[3] or Hegi, for patients with unmethylated MGMT
of 12.7 (RT/TMZ) vs. 11.8 months (RT) [43]. Patients
with non-methylated MGMT derived the greatest
benefit after treatment with nimotuzumab: MOS, 19.6
months (arm A) vs 15.0 months (Arm B) [23]. The
authors concluded that nimotuzumab shows a clear
trend towards efficacy in MGMT non-methylated
glioblastoma patients together with an excellent safety
profile [23]. Our finding is comparable to the results
of the German Phase III study, where the combin-
ation of nimotuzumab/RT/TMZ showed the greatest
advantage over RT/TMZ in the subset of patients
with non-methylated MGMT, who are resistant to the
alkylating agent, via direct DNA repair [43]. Nimotuzumab
didn’t significantly improve the rates of objective
response or disease control. However, it increases PFS
and overall survival, demonstrating its predominant
cytostatic effect and its role in controlling the tumor
progression rate.
Overall, patients achieved a lower survival than
reported for AA and GBM, particularly if treated
with placebo. This poor outcome can be explained
by the baseline characteristics of the patient popula-
tion: 29 patients (41.4%) were older than 50, 20
patients (28.6%) had a KPS of 60 or 70, 18 patients(25.7%) had just a biopsy, while only 7 patients
(10%) got a gross tumor resection. Lower KPS, lack
of debulking surgery and older ages are strong
predictors of poor outcome, according the recursive
portioning analysis proposed by RTOG and validated
by EORTC [44,45].
So far, other EGFR antagonists have resulted in
limited clinical activity in glioma patients [29-42].
Cetuximab has a low single-agent activity in patients
with recurrent HGG [30]. Furthermore, erlotinib,
when used in the recurrent setting has shown to be
marginally beneficial [31-37]. For the newly diag-
nosed patients, erlotinib co-administered with radio-
therapy and temozolomide was not efficacious [39].
We speculate that the lack of efficacy of other EGFR
antagonists might be associated with reduced drug
exposure. Treatment with cetuximab, erlotinib and gefitinib
were maintained as long as there were no unacceptable
safety concerns or until disease progression. Since these
EGFR antagonists can induce severe acne-like rash toxicity,
hypomagnesia and diarrhea, toxicity might have prevented
protracted therapy.
Conclusions
In this randomized, double blind, placebo-controlled
trial, nimotuzumab continues to show an excellent safety
profile (consistent with an international pharmacovigilance
data base of 17,451 patients), and survival benefit in
patients with high grade glioma in combination with
irradiation.
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